 The FDA has approved Novo Nordisk ASs NYSE: NVO 2.0 mg dose of Ozempic once-weekly semaglutide subcutaneous injection, a glucagon-like peptide-1 GLP-1 analog for type 2 diabetes. Ozempic is now approved in the US at 0.5 mg,1.0 mg, and 2.0 mg doses to treat type 2. 